In 2017, Rosa “Rosie” S. experienced pain in her abdomen. Though she saw several specialists, no one could seem to figure out what was wrong.
“I was having abdominal pain and was bloated,” shares Rosie, a Scottsdale resident who has worked as a Spanish English interpreter and claims handler for a large insurance company.
“They couldn’t figure out what was going on with me. My stomach looked like I was pregnant. I started getting fevers.”
Finally getting answers
Rosie finally found a doctor who conducted blood tests and used a CT scan to discover that she had a liposarcoma, the most common type of soft tissue sarcoma, a cancer that arises from fatty tissues. The tumor that surgeons eventually removed weighed 30 pounds.
Rosie underwent radiation treatments in 2018, but the tumor came back in 2019. After her second surgery, the tumor returned again in 2020. This time, to get to the tumor, she also had one of her kidneys and her gallbladder removed.
“It wasn’t that the cancer spread to those organs,” shares Rosie. “It was just so close to them that they couldn’t surgically remove the tumor without being able to remove the other organs as well.”
When the cancer again returned in 2022, it was determined that it was inoperable. She couldn’t have the cancer surgically removed without risking her other kidney. She again was gaining weight.
Rosie had always been very active, but this time she began gaining so much weight that she became immobile, barely able to walk and at times needing a wheelchair. She was recommended for a clinical trial at the HonorHealth Research Institute.
Positive results with the clinical trial
Under the care of Michael Gordon, MD, an oncologist and the HonorHealth Research Institute’s chief medical officer and medical director of the Institute’s Multispecialty Research Division, Rosie began the Agenus clinical trial in October 2022.
As Rosie’s tumor began shrinking in 2023, she began losing weight and became more self-sufficient, and recently began her third year of her clinical trial. “I’m very grateful for that,” Rosie says. I’m independent again. It feels great; it really does.”
She is grateful to Dr. Gordon and the rest of the Institute team. “They’re like my angels,” Rosie adds.
Today, her prognosis is good. After two years on the study, Rosie continues to have a positive response. She feels great and her quality of life has drastically improved.
“I recommend the Institute to everyone,” Rosie says. “If they are looking for a last hope, they might find it there.”
Related content
Offering patients innovative treatment options
The HonorHealth Research Institute is at the front of today’s most important health questions. Established in 2005, the Institute has become a patient destination for treatments often available nowhere else.
Experts provide high-quality cancer care
The HonorHealth Cancer Care team is here to care for you wherever you are on your cancer journey. From preventive care to oncology and hematology services to survivorship resources, we’re here for you every step of the way.
Clinical trial helps patient find relief from brain tumor
Diane had a rare condition known as neuroendocrine cancer and had four tumors in her brain. As part of a clinical trial, she was treated with a new type of radioactive tiles that attacked any remaining cancer cells after surgery.